H.C. Wainwright raised the firm’s price target on eFfector Therapeutics to $24 from $5 and keeps a Buy rating on the shares. The target adjustment reflects the 1-for-25 reverse stock split of the company’s common stock. The firm now expects Effector’s cash runway to take it into Q1 of 2025, “past two important data milestones.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EFTR:
- eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
- eFFECTOR Therapeutics Regains Nasdaq Compliance Status
- eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- eFFECTOR Therapeutics Secures $15M in Direct Offering
- eFfector to sell 1.49M shares at $10.075 in registered direct offering
